Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial
August 09, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
July 31, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
July 18, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, July 18, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover
July 11, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, July 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Selected for the Russell Microcap Index
June 26, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market
June 21, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer...
Moleculin Receives Approval for Leukemia Clinical Trial
June 20, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors
June 12, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
June 06, 2018 09:09 ET
|
Moleculin Biotech, Inc.
HOUSTON, June 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Invited to Present to International BioForum 2018 Conference
May 24, 2018 08:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, May 24, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...